Celgene has today confirmed that it will acquire Juno Therapeutics for $9 billion, and says the move will make it a leader in cell immunotherapy. The price is a significant premium on the $5.5 bn ...

Celgene has acquired Gloucester Pharmaceuticals ... Research at the Massey Cancer Center of Virginia Commonwealth University, Virginia, USA. “However, there is no consensus concerning the ...

Chemotherapy and immunotherapy followed by de-escalated chemoradiation showed increased survival and reduced side effects in aggressive head and neck cancers that are not associated with human ...

It’s been a week notable for developments in neurology medicine, with Celgene exercising an option to buy a potential multiple sclerosis drug, as GW Pharma prepares a filing for a phase 3 ...

Celgene (Warren, NJ), a developer of chirally pure drugs, agreed on June 30 to purchase gene-regulation firm Signal Pharmaceuticals (San Diego, CA) for $200 million in an all-stock deal.